Background: Cerebrospinal fluid leakage and other complications followed from transsphenoidal surgery when removing pituitary tumours are rare but serious. Through studies and clinical trials, Tachosil® has proven to be an effective sealing agent, thus in preventing complications. Methods: Data of 82 patients that underwent transsphenoidal surgery for removing pituitary tumours in Ullevål University Hospital in the years 2006-2008 was collected. Statistical tests were performed to test the differences between the sealing techniques used during surgery in terms of patient characteristics, complication rates and length of stay. Costs expressed in 2009 NOK of the sealing agents (Tachosil® and Neuro-Patch®), intensity care unit and standard ward care were identified. Results: The complication rate was 25% in the Neuro-Patch® group and 23% in the Tachosil® group (p=0.726). The mean ICU LOS in the Tachosil® group was 1.42 days and SWC LOS was 5.92 days, while the numbers were 1.93 and 7.93 in the Neuro-Patch® group. The differences between the two groups according to length of stay were not statistically significant. The mean ICU cost of a patient in the Neuro-Patch® group was NOK 52,200 and NOK 38,250 in the Tachosil® group (p=0.265). The mean SWC cost in the Neuro-Patch® group was NOK 38,080 and NOK 28,400 in the Tachosil® group (p=0.856). The mean cost of the sealing product was NOK 394 in the Neuro-Patch® group and NOK 1,261 in the Tachosil® group (p<0.001).Conclusion: The results of this study do not provide any evidence that Tachosil® is superior in terms of complications or length of stay.